Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
06 September 2024 - 9:00PM
Houston, Texas and Tuebingen, Germany,
September 06, 2024 – Immatics N.V. (NASDAQ: IMTX,
“Immatics” or the “Company”), a clinical-stage biopharmaceutical
company active in the discovery and development of T
cell-redirecting cancer immunotherapies, today announced that
updated clinical data on its lead cell therapy candidate,
ACTengine® IMA203 targeting PRAME, will be presented at the 21st
International Congress of the Society for Melanoma Research.
Oral presentation
Date / Time: October 11, 2024 /
8:00 – 8:20 am Central Daylight TimeSession:
Plenary Session 1 – Developmental Immunotherapy (Cellular
Immunotherapy, Vaccines, and New
Checkpoints)Title: ACTengine IMA203 TCR-T
targeting PRAME in PD1-refractory metastatic melanoma – Clinical
UpdatePresenter: Martin Wermke, M.D. (University
Hospital Dresden, Germany)
About IMA203
ACTengine® IMA203 T cells is an autologous T
cell product with a genetically modified, pairing-enhanced TCR
directed against an HLA-A*02-presented peptide derived from
preferentially expressed antigen in melanoma (PRAME). This peptide
is frequently expressed in a large variety of solid cancers,
thereby supporting the program’s potential to address a broad
cancer patient population. Immatics’ PRAME peptide is present at a
high copy number per tumor cell and is homogeneously and
specifically expressed in tumor tissue. The peptide has been
identified and characterized by Immatics’ proprietary mass
spectrometry-based target discovery platform, XPRESIDENT®. Through
its proprietary TCR discovery and engineering platform XCEPTOR®,
Immatics has generated a highly specific T cell receptor (TCR)
against this target for its TCR-based cell therapy approach,
ACTengine® IMA203.
ACTengine® IMA203 TCR-T is currently being
evaluated in a Phase 1 trial as IMA203 monotherapy, and as a
second-generation IMA203CD8 (GEN2) monotherapy, where
IMA203-engineered T cells are co-transduced with a CD8αβ
co-receptor, thereby leveraging the power of both CD4+ and CD8+ T
cells. As previously reported, IMA203 in combination with an immune
checkpoint inhibitor has been deprioritized.
About ImmaticsImmatics combines
the discovery of true targets for cancer immunotherapies with the
development of the right T cell receptors with the goal of enabling
a robust and specific T cell response against these targets. This
deep know-how is the foundation for our pipeline of Adoptive Cell
Therapies and TCR Bispecifics as well as our partnerships with
global leaders in the pharmaceutical industry. We are committed to
delivering the power of T cells and to unlocking new avenues for
patients in their fight against cancer.
Immatics intends to use its website
www.immatics.com as a means of disclosing material non-public
information. For regular updates you can also follow us on X,
Instagram and LinkedIn.
For more information, please contact:
Media |
|
Trophic Communications |
|
Phone: +49 171 3512733 |
|
immatics@trophic.eu |
|
Immatics N.V. |
|
Jordan Silverstein |
|
Head of Strategy |
|
Phone: +1 346 319-3325 |
|
InvestorRelations@immatics.com |
|
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Dec 2024 to Jan 2025
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Jan 2024 to Jan 2025